Furosemide vs Hydrochlorothiazide

For hypertension, thiazide diuretics including HCTZ are considered first-line therapy based on decades of clinical trial evidence ^[3]. The ALLHAT trial demonstrated that chlorthalidone (a thiazide-like diuretic similar to HCTZ) was as effective as amlodipine and lisinopril for preventing cardiovascular events ^[3]. HCTZ at 12.5-50 mg daily produces sustained blood pressure reduction over 24 hours ^[2]. Furosemide is not a preferred antihypertensive because its short duration of action (6-8 hours) and intermittent diuresis make blood pressure control less consistent throughout the day ^[1].

For edema management (heart failure, nephrotic syndrome, liver cirrhosis), furosemide is clearly superior due to its much greater diuretic potency ^[1]. Loop diuretics can achieve 15-25% sodium excretion, compared to 5-10% for thiazides. Furosemide works even in patients with significantly reduced kidney function (GFR < 30 mL/min), where thiazides lose much of their effectiveness ^[1][4].

For acute decompensated heart failure, intravenous furosemide is the standard of care for rapid volume removal, with no role for HCTZ in this setting ^[4].

Furosemide's most common side effects include dehydration, electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia), dizziness, hypotension, and ototoxicity (hearing changes, usually dose-related and reversible) ^[1]. Its potent diuresis can cause significant volume depletion, especially in elderly patients or those with restricted fluid intake.

HCTZ's side effects include hypokalemia (less severe than furosemide), hyperuricemia (which can trigger gout), hyperglycemia (can worsen diabetes), hypercalcemia, hyponatremia, dizziness, and photosensitivity ^[2]. HCTZ has a notable metabolic side effect profile — it can raise blood glucose, uric acid, LDL cholesterol, and triglycerides ^[2][3].

A key difference: furosemide causes calcium excretion (hypocalcemia), while HCTZ reduces calcium excretion (hypercalcemia) ^[1][2]. This makes HCTZ potentially beneficial for patients with osteoporosis or calcium kidney stones, while furosemide may worsen calcium loss.

Both require periodic monitoring of electrolytes and kidney function ^[1][2].

Both are available as very inexpensive generics ^[5]. Generic furosemide (20 mg, 40 mg, 80 mg) costs $4-$10 for a 30-day supply. Generic HCTZ (12.5 mg, 25 mg, 50 mg) costs $4-$10 for a 30-day supply. Both qualify for $4 generic programs at most pharmacies. Insurance coverage is universal for both.

HCTZ is typically taken once daily in the morning and provides relatively steady blood pressure control over 24 hours ^[2]. Furosemide is taken 1-2 times daily (morning and noon typically, to avoid nighttime diuresis), and its effect peaks within 1-2 hours with prominent urination for 4-6 hours ^[1].

Furosemide is available as tablets, oral solution, and injectable (IV/IM), giving it versatility for inpatient and outpatient use ^[1]. HCTZ is available only as oral tablets and capsules. The intense diuretic effect of furosemide can be inconvenient for daily activities, as patients must plan around bathroom access.

The choice between furosemide and HCTZ depends primarily on whether the clinical goal is volume/edema management or blood pressure control ^[1][2].

HCTZ is the appropriate choice for most patients with hypertension, where it is a proven first-line agent with strong cardiovascular outcome data ^[2][3]. It is also appropriate when combination antihypertensive therapy is needed.

Furosemide is the appropriate choice for edema from heart failure, liver disease, or kidney disease, acute fluid overload, and patients with significant renal impairment (GFR < 30) where thiazides are ineffective ^[1][4].

This information is for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine which diuretic is appropriate for your condition.